WordNet
- any malignant tumor derived from epithelial tissue; one of the four major types of cancer
PrepTutorEJDIC
- がん,がん腫
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/04/13 17:49:12」(JST)
wiki en
| Carcinoma | |
|---|---|
| Classification and external resources | |
Micrograph of a lung primary small cell carcinoma, a type of carcinoma. The clustered cancerous cells consist primarily of nucleus (purple); they have only a scant rim of cytoplasm. The surrounding pale staining, discoid cells are red blood cells. Cytopathology specimen. Field stain. |
|
| ICD-O: | 8010-8580 |
| MeSH | D002277 |
Carcinoma (Gk. karkinos, or "crab", and -oma, "growth") is the medical term for the most common type of cancer occurring in humans. Put simply, a carcinoma is a cancer that begins in a tissue that lines the inner or outer surfaces of the body, and that generally arises from cells originating in the endodermal or ectodermal germ layer during embryogenesis.[1] More specifically, a carcinoma is tumor tissue derived from putative epithelial cells whose genome has become altered or damaged to such an extent that the cells become transformed, and begin to exhibit abnormal malignant properties.
Contents
|
Carcinoma of unknown primary (CUP)
The term carcinoma has also come to encompass malignant tumors composed of transformed cells whose origin or developmental lineage is unknown (see CUP), but that possess certain specific molecular, cellular, and histological characteristics typical of epithelial cells. This may include the production of one or more forms of cytokeratin or other intermediate filaments, intercellular bridge structures, keratin pearls, and/or tissue architectural motifs such as stratification or pseudo-stratification.[2][3]
Pathogenesis of cancer
Cancer occurs when a single progenitor cell accumulates mutations and other changes in the DNA, histones, and other biochemical compounds that make up the cell's genome. The cell genome controls the structure of the cell's biochemical components, the biochemical reactions that occur within the cell, and the biological interactions of that cell with other cells. Certain combinations of mutations in the given progenitor cell ultimately result in that cell (also called a cancer stem cell) displaying a number of abnormal, malignant cellular properties that, when taken together, are considered characteristic of cancer, including:
- the ability to continue to divide perpetually, producing an exponentially (or near-exponentially) increasing number of new malignant cancerous "daughter cells" (uncontrolled mitosis);
- the ability to penetrate normal body surfaces and barriers, and to bore into or through nearby body structures and tissues (local invasiveness);
- the ability to spread to other sites within the body (metastasize) by penetrating or entering into the lymphatic vessels (regional metastasis) and/or the blood vessels (distant metastasis).
If this process of continuous growth, local invasion, and regional and distant metastasis is not halted via a combination of stimulation of immunological defenses and medical treatment interventions, the end result is that the host suffers a continuously increasing burden of tumor cells throughout the body. Eventually, the tumor burden increasingly interferes with normal biochemical functions carried out by the host's organs, and death ultimately ensues.
Pathogenesis of carcinoma
Carcinoma is but one form of cancer - one composed of cells that have developed the cytological appearance, histological architecture, or molecular characteristics of epithelial cells.[2][3] A progenitor carcinoma stem cell can be formed from any of a number of oncogenic combinations of mutations in a totipotent cell,[citation needed] a multipotent cell,[citation needed]or a mature differentiated cell.[citation needed]
Epidemiology of carcinoma
- Demography (Age, Race, Gender, etc.)
While cancer is generally considered a disease of old age, children can also develop cancer.[4] In contrast to adults, carcinomas are exceptionally rare in children.[citation needed].
- Causes
Smoking, environment, etc.
In situ
The term Carcinoma in situ (or CIS) refers to a small, localized carcinoma that has not yet invaded through the epithelial basement membrane delimiting the carcinomatous cells from adjacent normal cells. CIS is a pre-invasive cancer, and not a pre-malignant entity.[5]
Nearly all cases of CIS will continue to grow and progress until they begin to infiltrate and penetrate into and through the basal membrane or other/adjacent structures. Once invasion occurs, they are no longer considered CIS lesions, but truly invasive carcinomas. If the lesion can be completely removed via surgical resection, cryotherapy, laser ablation, or some other locally-targeted treatment modality before frank invasion and metastasis develops, cure rates for CIS approach 100%.
In some cases, CIS lesions may gradually re-assume more normal-looking cytological and histological characteristics, thereby becoming lower-grade neoplasms. Biologically, this can very often result in less aggressive, slower-growing neoplasms. Indeed, the appearance of the component cells and local tissue architecture at the local site of the CIS may eventually normalize to the point where the transformed cells no longer meet the consensus requirements necessary for it to be classified as a carcinoma. Therefore, this abnormality would no longer qualify as a true cancer.
These changes are also usually accompanied by decreases in surface area and/or volume of the abnormal area. In some not-insignificant proportion of cases, the abnormal cells/tissue may disappear entirely, with the resulting local area containing only normal-appearing tissue. The process is often referred to by oncologists and pathologists as regression of the CIS lesion. Regression of CIS effectively results in the progressive conversion of a malignant neoplasm to a benign one, to a localized area of normal or near-normal tissue, with or without associated scar tissue, which often forms secondary to apoptosis, necrosis, and fibrosis.
Regression is most often manifested after exposure to prolonged changes in the quality and intensity of environmental and/or immunological stimuli.
A very common example is the regression in some lesions of CIS located in the main central and segmental bronchi of the lung. Many pre-invasive lesions in cases of squamous cell carcinoma often regress after long-term reduced exposure of the affected cells and tissues to the original environmental carcinogenic stimulus, such as that seen after long-term abstention from tobacco smoking.[6] Another relatively common example is the immunologically-driven clearing of Human Papilloma Virus HPV from transformed epithelial cells of the uterine cervix, which results in regression of cervical CIS lesions.
Classification of carcinomas
Malignant neoplasms are exceptionally heterogeneous entities, reflecting the wide variety, intensity, and potency of various carcinogenic promoters.[7]
To date, no simple and comprehensive method for classifying them has yet been devised and accepted within the scientific community.[3]
Traditionally, however, malignancies have generally been classified into various taxa using a combination of criteria, including:[2]
One commonly used classification scheme classifies these major cancer types on the basis of cell genesis, specifically:
- Their (putative) cell (or cells) of origin
- Epithelial cells => carcinoma
- Non-hematopoietic mesenchymal cells => sarcoma
- Hematopoietic cells
- bone marrow-derived cells that normally mature in the bloodstream => Leukemia
- bone marrow-derived cells that normally mature in the lymphatic system => Lymphoma
- Germ cells => Germinoma
Other criteria that play a role in a cancer diagnosis include:
- The degree to which the malignant cells resemble their normal, untransformed counterparts
- the appearance of the local tissue and stromal architecture
- the anatomical location from which tumors arise
- genetic, epigenetic, and molecular features
Histological types and variants of carcinoma
- Adenocarcinoma
- (adeno = gland) Refers to a carcinoma featuring microscopic glandular-related tissue cytology, tissue architecture, and/or gland-related molecular products, e.g., mucin.
- Squamous cell carcinoma
- Refers to a carcinoma with observable features and characteristics indicative of squamous differentiation (intercellular bridges, keratinization, squamous pearls).
- Adenosquamous carcinoma
- Refers to a mixed tumor containing both adenocarcinoma and squamous cell carcinoma, wherein each of these cell types comprise at least 10% of the tumor volume.
- Anaplastic carcinoma
- Refers to a heterogeneous group of high-grade carcinomas that feature cells lacking distinct histological or cytological evidence of any of the more specifically differentiated neoplasms. These tumors are referred to as Anaplastic or Undifferentiated carcinomas.
- Large cell carcinoma
- Composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.
- Small cell carcinoma
- Cells are usually round and are less than approximately 3 times the diameter of a resting lymphocyte and little evident cytoplasm. Occasionally, small cell malignancies may themselves have significant components of slightly polygonal and/or spindle-shaped cells.[8]
There are a large number of rare subtypes of anaplastic, undifferentiated carcinoma. Some of the more well known include the lesions containing pseudo-sarcomatous components: spindle cell carcinoma (containing elongated cells resembling connective tissue cancers), giant cell carcinoma (containing huge, bizarre, multinucleated cells), and sarcomatoid carcinoma (mixtures of spindle and giant cell carcinoma). Pleomorphic carcinoma contains spindle cell and/or giant cell components, plus at least a 10% component of cells characteristic of more highly differentiated types (i.e. adenocarcinoma and/or squamous cell carcinoma). Very rarely, tumors may contain individuals components resembling both carcinoma and true sarcoma, including carcinosarcoma and pulmonary blastoma.[8]
Frequent organ sites of carcinoma
- Lung: Carcinoma comprises >98% of all lung cancers.
- Breast: Nearly all breast cancers are ductal carcinoma.
- Prostate: The most common form of carcinoma of the prostate is adenocarcinoma.
- Colon and rectum: Nearly all malignancies of the colon and rectum are either adenocarcinoma or squamous cell carcinoma.
- Pancreas: Pancreatic carcinoma is almost always of the adenocarcinoma type and is highly lethal.
Some carcinomas are named for their or the putative cell of origin, (e.g.hepatocellular carcinoma, renal cell carcinoma).
Invasion and metastasis of carcinomas
The hallmark of a malignant tumor is its tendency to invade and infiltrate local and adjacent structures and, eventually, spread from the site of its origin to non-adjacent regional and distant sites in the body, a process called metastasis. If unchecked, tumor growth and metastasis eventually creates a tumor burden so great that the host succumbs. Carcinoma metastasizes through both the lymph nodes and the blood.
Diagnosis
Carcinomas can be definitively diagnosed through biopsy, including fine-needle aspiration (FNA), core biopsy, or subtotal removal of single node,.[9] Microscopic examination by a pathologist is then necessary to identify molecular, cellular, or tissue architectural characteristics of epithelial cells.
Types of carcinoma (by ICD-O code)
- (8010-8045) Epithelial neoplasms, NOS
- (8050-8080) Squamous cell neoplasms
- (M8070/3) Squamous cell carcinoma, NOS
- (8090-8110) Basal cell neoplasms
- (M8090/3) Basal cell carcinoma, NOS
- (8120-8130) Transitional cell carcinomas
- (8140-8380) Adenocarcinomas
- (M8140/3) Adenocarcinoma, NOS
- (M8142/3) Linitis plastica
- (M8155/3) Vipoma
- (M8160/3) Cholangiocarcinoma
- (M8170/3) Hepatocellular carcinoma, NOS
- (M8200/3) Adenoid cystic carcinoma
- (M8312/3) Renal cell carcinoma
- (M8312/3) Grawitz tumor
- (8390-8420) Adnexal and Skin appendage Neoplasms
- (8430-8439) Mucoepidermoid Neoplasms
- (8440-8490) Cystic, Mucinous and Serous Neoplasms
- (8500-8540) Ductal, Lobular and Medullary Neoplasms
- (8550-8559) Acinar cell neoplasms
- (8560-8580) Complex epithelial neoplasms
Staging
Staging of carcinoma refers to the process of combining physical/clinical examination, pathological review of cells and tissues, surgical techniques, laboratory tests, and imaging studies in a logical fashion to obtain information about the size of the neoplasm and the extent of its invasion and metastasis.
Carcinomas are usually staged with Roman numerals. In most classifications, Stage I and Stage II carcinomas are confirmed when the tumor has been found to be small and/or to have spread to local structures only. Stage III carcinomas typically have been found to have spread to regional lymph nodes, tissues, and/or organ structures, while Stage IV tumors have already metastasized through the blood to distant sites, tissues, or organs.
In some types of carcinomas, Stage 0 carcinoma has been used to describe carcinoma in situ, and occult carcinomas detectable only via examination of sputum for malignant cells (in lung carcinomas).
In more recent staging systems, substages (a, b, c) are becoming more commonly used to better define groups of patients with similar prognosis or treatment options.
Carcinoma stage is the variable that has been most consistently and tightly linked to the prognosis of the malignancy.
The criteria for staging can differ dramatically based upon the organ system in which the tumor arises. For example, the colon[10] and bladder cancer[11] staging system relies on depth of invasion, staging of breast carcinoma is more dependent on the size of the tumor, and in renal carcinoma, staging is based on both the size of the tumor and the depth of the tumor invasion into the renal sinus. Carcinoma of the lung has a more complicated staging system, taking into account a number of size and anatomic variables.[12]
The UICC/AJCC TNM systems are most often used.[clarification needed] [1] For some common tumors, however, classical staging methods (such as the Dukes classification for colon cancer) are still used.
Grading
Grading of carcinomas refers to the employment of criteria intended to semi-quantify the degree of cellular and tissue maturity seen in the transformed cells relative to the appearance of the normal parent epithelial tissue from which the carcinoma derives.
Grading of carcinoma is most often done after a treating physician and/or surgeon obtains a sample of suspected tumor tissue using surgical resection, needle or surgical biopsy, direct washing or brushing of tumor tissue, sputum cytopathology, etc. A pathologist then examines the tumor and its stroma, perhaps utilizing staining, immunohistochemistry, flow cytometry, or other methods. Finally, the pathologist classifies the tumor semi-quantitatively into one of three or four grades, including:
- Grade 1, or well differentiated: there is a close, or very close, resemblance to the normal parent tissue, and the tumor cells are easily identified and classified as a particular malignant histological entity;
- Grade 2, or moderately differentiated: there is considerable resemblance to the parent cells and tissues, but abnormalities can commonly be seen and the more complex features are not particularly well-formed;
- Grade 3, or poorly differentiated: there is very little resemblance between the malignant tissue and the normal parent tissue, abnormalities are evident, and the more complex architectural features are usually rudimentary or primitive;
- Grade 4, or undifferentiated carcinoma: these carcinomas bear no significant resemblance to the corresponding parent cells and tissues, with no visible formation of glands, ducts, bridges, stratified layers, keratin pearls, or other notable characteristics consistent with a more highly differentiated neoplasm.
Although there is definite and convincing statistical correlation between carcinoma grade and tumor prognosis for some tumor types and sites of origin, the strength of this association can be highly variable. It may be stated generally, however, that the higher the grade of the lesion, the worse is its prognosis.[13][14]
See also
- Cancer
- Sarcoma
- Hematological malignancy
- Basal cell carcinoma
References
Notes
- ^ http://www.medterms.com/script/main/art.asp?articlekey=20677
- ^ a b c Berman JJ (November 2004). "Tumor taxonomy for the developmental lineage classification of neoplasms". BMC Cancer 4: 88. doi:10.1186/1471-2407-4-88. PMC 535937. PMID 15571625.
- ^ a b c Berman JJ (March 2004). "Tumor classification: molecular analysis meets Aristotle". BMC Cancer 4: 10. doi:10.1186/1471-2407-4-10. PMC 415552. PMID 15113444.
- ^ Kuriakose MA, Hicks WL, Loree TR, Yee H (August 2001). "Risk group-based management of differentiated thyroid carcinoma". J R Coll Surg Edinb 46 (4): 216–23. PMID 11523714.
- ^ Banerjee AK (April 2009). "Preinvasive lesions of the bronchus". J Thorac Oncol 4 (4): 545–51. doi:10.1097/JTO.0b013e31819667bd. PMID 19279508.
- ^ Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S (March 2010). "Natural history of bronchial preinvasive lesions". Cancer Metastasis Rev. 29 (1): 5–14. doi:10.1007/s10555-010-9214-7. PMID 20112052.
- ^ Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R (June 1985). "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases". Hum. Pathol. 16 (6): 569–79. doi:10.1016/S0046-8177(85)80106-4. PMID 2987102.
- ^ a b Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad et al., eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN 92-832-2418-3. Retrieved 27 March 2010.
|displayeditors=suggested (help) - ^ Wagman LD (2008). "Principles of Surgical Oncology". In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ. Cancer Management: A Multidisciplinary Approach (11th ed.).
- ^ Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 2010;134:837-52.
- ^ Sharir S. Update on clinical and radiological staging and surveillance of bladder cancer. Can J Urol 2006;13 Suppl 1:71-6.
- ^ Pepek JM, Chino JP, Marks LB, D'amico TA, Yoo DS, Onaitis MW, Ready NE, Hubbs JL, Boyd J, Kelsey CR. J Thorac Oncol 2011;6:757-61.
- ^ Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, Sugimura H, Pankratz VS, Yang P. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006;131:1014-20.
- ^ "Poorly differentiated carcinoma of unknown primary site". Retrieved 2010-04-22.
External links
- Media related to Carcinoma at Wikimedia Commons
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 皮膚扁平上皮癌（SCC）の臨床的特徴および診断 clinical features and diagnosis of cutaneous squamous cell carcinoma scc
- 2. 皮膚扁平上皮癌の治療および予後 treatment and prognosis of cutaneous squamous cell carcinoma
- 3. 顔面病変のダーモスコピー dermoscopy of facial lesions
- 4. Epidermodysplasia verruciformis
- 5. Dermoscopic algorithms for skin cancer triage
English Journal
- Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast.
- Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT.SourceDepartment of Pathology, The University of Texas Health Science Center Department of Pathology, Houston, TX 77030, USA.
- The American journal of surgical pathology.Am J Surg Pathol.2012 Sep;36(9):1353-8. doi: 10.1097/PAS.0b013e318259ef7f.
- Mammary Paget disease (MPD) is considered an intraepidermal manifestation of an underlying mammary carcinoma. In contrast to extramammary Paget disease, invasion of mammary Paget cells into the dermis (invMPD) has not been reported, except for 2 cases described in Rosen's textbook. Our study was des
- PMID 22895267
- Pharmacotherapy of actinic keratosis: an update.
- Berman B, Amini S.SourceCenter for Clinical and Cosmetic Research, Skin and Cancer Associates, Aventura, FL 33180, USA. bbmdphd@gmail.com
- Expert opinion on pharmacotherapy.Expert Opin Pharmacother.2012 Sep;13(13):1847-71.
- INTRODUCTION: Actinic keratosis (AK) represents the initial intraepidermal manifestation of abnormal keratinocyte proliferation, with the potential of progression to squamous cell carcinoma (SCC). Few visible AKs lead to the use of lesion-directed treatments, including ablative and/or surgical proce
- PMID 22888917
Japanese Journal
- 肛門周囲皮膚の腫瘍性病変の診断・治療について
- 佐原 力三郎
- 日本大腸肛門病学会雑誌 61(10), 971-975, 2008-10-01
- 肛門周囲皮膚の腫瘍性病変は比較的稀な疾患である．肛門縁より皮膚側の領域において発生する皮膚病変が主体となる．この部位は患者自身の視野に入りにくいので自覚症状がないうちは発見されにくい．症状出現してからも部位の特殊性から専門的な相談すら躊躇してしまい治療が遅れる傾向がある．患者の受診先として肛門科，皮膚科両科に分かれ，肛門科的には慢性の肛門周囲湿疹として誤診されやすい．肛門周囲皮膚に発生する基底細胞 …
- NAID 10024924504
- ヘアレスマウスを用いた日光角化症モデルの確立
- 米山 茂樹,塩田 徹哉,藤坂 紳一,高田 実,斎田 俊明,峰松 澄穂,武井 啓司,宮木 末雄
- Skin cancer : official organ of the Japanese Society for Skin Cancer = 皮膚悪性腫瘍研究会機関誌 21(2), 226-231, 2006-10-31
- ヘアレスマウスに中波長紫外線 (UV-B) を照射し, 薬効試験評価系として適切な日光角化症モデルの作製条件を探索した。雌性ヘアレスマウスに0.24J/cm2のUV-B (波長領域280〜360nm, 波長ピーク306nm) を8, 12, 16週間照射し (週3回) , その後引き続き4〜8週間の観察期間を設けた。いずれの照射群においても腫瘤形成が認められたが, 照射期間および照射終了後観察期間 …
- NAID 10022600671
Related Links
- 13 Nov 2011 ... intraepidermal SCC. Authoritative facts about the skin from the New Zealand Dermatological Society.
- Bowen's disease (BD) (also known as "squamous cell carcinoma in situ" :655) is a neoplastic skin disease, it can be considered as an early stage or intraepidermal form of squamous cell carcinoma. It was named after John T. Bowen.
Related Pictures
★リンクテーブル★
| リンク元 | 「表皮内癌」「表皮内がん」 |